

Suven Life Sciences to Present Key Clinical Updates on Samelisant at World Sleep 2025 International Conference in Singapore, 5-10, Sept 2025.

Hyderabad, India (05-Sept-2025) – *Suven Life Sciences*, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, today announced **its participation in World Sleep 2025 conference, a premier international congress dedicated to sleep medicine and research, taking place in Singapore from September 5–10, 2025. Suven will present multiple scientific presentations detailing clinical progress on its lead investigational candidate Samelisant, highly potent and selective histamine H3 receptor inverse agonist in development for sleep disorders.**

1. Samelisant (SUVN-G3031) Alleviates Excessive Daytime Sleepiness in Narcolepsy Patients: Results from a Phase-2 Study.
2. Rationale and Study Design for the Evaluation of Samelisant (SUVN-G3031) in a Phase-2 Study for the Treatment of Cataplexy in Patients with Narcolepsy.
3. Samelisant, a potent and selective histamine H3 receptor inverse agonist: safety, tolerability and pharmacokinetics following single and multiple ascending doses in healthy subjects.
4. Rationale and Study Design of Phase-3 Clinical Development Program for Samelisant (SUVN-G3031) in the Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.

Suven Life Sciences will also be exhibiting at Booth # 532 during the conference. Attendees are invited to visit the booth to learn more about the company's CNS pipeline, ongoing clinical development plans of Samelisant, and opportunities for scientific and strategic collaborations.

"We are excited to share the latest progress on Samelisant with the international sleep research community at World Sleep 2025. Following encouraging Phase-2 results, our clinical development programs for Samelisant in sleep disorders are moving forward. We believe Samelisant has the potential to offer a meaningful new treatment option for patients living with hypersomnia and related sleep disorders." said Mr. Venkat Jasti, Chairman and MD of Suven Life Sciences.

The world sleep 2025 abstracts are available at the website: <https://worldsleepcongress.com/>

About Samelisant (SUVN-G3031): Samelisant is a novel, potent, selective, brain penetrant, and orally active Histamine-3 (H3) receptor inverse agonist. Samelisant through H3 receptor blockade elevates histamine, norepinephrine, and dopamine in the brain, a salient feature required for the treatment of EDS and cataplexy. Samelisant also exhibited wake-promoting activity in orexin knock-out mice (an animal model of narcolepsy).

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad - 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study ongoing). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website <http://www.suven.com>

Risk Statement: Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad - 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com